Learn Before
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice
Tian, J., Patel, N., Haupt, R., Zhou, H., Weston, S., Hammond, H., . . . Smith, G. (2020, January 01). SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice. Retrieved August 17, 2020, from https://www.biorxiv.org/content/10.1101/2020.06.29.178509v1
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Temporal increase in D614G mutation of SARS-CoV-2 in the Middle East and North Africa: Phylogenetic and mutation analysis study
The SARS-CoV-2 Spike mutation D614G increases entry fitness across a range of ACE2 levels, directly outcompetes the wild type, and is preferentially incorporated into trimers
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice